{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:50:46Z","timestamp":1790398246700,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diabetes is the common metabolic disorder. Empagliflozin is a new medication that acts as a sodium\u2010glucose cotransporter 2 (SGLT2) inhibitor. It promotes increased glucose excretion through urine, which helps improve blood sugar control, enhances glucose metabolism, and reduces glucotoxicity and insulin resistance. This study aimed to investigate and compare the effects of adding empagliflozin to a medication regimen on peripheral neuropathy in diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This study involved 50 patients with diabetic neuropathy, confirmed by the Michigan Neuropathy Screening Instrument, who were randomly assigned to two groups. The control group continued their previous medication regimen with a placebo, while the treatment group added 10\u2009mg of empagliflozin daily to their existing regimen. At the start of the study, fasting blood glucose, haemoglobin A1c, serum creatinine levels and electrophysiological findings (including amplitude, latency and nerve conduction velocity) were assessed for all patients. These parameters were re\u2010evaluated at the end of the 20\u2010week intervention, and the results were analysed using statistical software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the end of the study, there was a significant reduction in both haemoglobin A1c and fasting blood glucose levels in the treatment group. Serum creatinine levels also significantly decreased. eGFR (estimated glomerular filtration rate) increased in the treatment group. In the Michigan Neuropathy Screening Instrument, the oral test score improved in the treatment group, but no significant difference was observed in the clinical examination scores. Additionally, electrophysiological testing showed a significant improvement in nerve conduction velocity in the treatment group. Latency also decreased in the treatment group, but no significant difference was observed in amplitude between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empagliflozin reduces blood glucose levels and improves kidney filtration function. It also enhances clinical symptoms and nerve conduction velocity in patients with diabetic neuropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70128","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:50:04Z","timestamp":1763704204000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type\n                    <scp>II<\/scp>\n                    Diabetes: A Double Blind Randomised Clinical Trial"],"prefix":"10.1002","volume":"8","author":[{"given":"Mohammadreza","family":"Vafaeinasab","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9453-4859","authenticated-orcid":false,"given":"Fatemeh","family":"Mirzaei Malekabad","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amidodin","family":"Khatibi","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Ghadiri\u2010Anari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Zare Bidaki","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raihane","family":"Azizi","sequence":"additional","affiliation":[{"name":"Diabetes Research Center Shahid Sadoughi University of Medical Sciences  Yazd Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"12","key":"e_1_2_9_2_1","article-title":"Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients","volume":"13","author":"Mehta S.","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-016-0039-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080008"},{"issue":"2","key":"e_1_2_9_5_1","first-page":"17","article-title":"Comparison of Two Supplementary Zinc Doses on Lipid Peroxidation in Diabetic Patients","volume":"2","author":"Sheikhpour R.","year":"2010","journal-title":"IJDO"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-010-9134-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010159\u20104\u2010201308200\u201000007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2017.08.005"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110379"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.708547"},{"issue":"12","key":"e_1_2_9_11_1","article-title":"New Insights Into the Use of Empagliflozin\u2014A Comprehensive Review","volume":"10","author":"Forycka J.","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_9_12_1","first-page":"364","article-title":"Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type\u20102 Diabetes","volume":"40","author":"Ndefo U. A.","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12064"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0126-x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"issue":"1","key":"e_1_2_9_16_1","first-page":"40","article-title":"A Survey on Herbal Medicines for Hypoglycemia in Diabetic Patients","volume":"4","author":"Sheikhpour R.","year":"2012","journal-title":"Iranian Journal of Diabetes and Obesity"},{"issue":"1","key":"e_1_2_9_17_1","first-page":"41","article-title":"New Insights Into the Effect of Diabetes and Obesity in Alzheimer's disease17","volume":"6","author":"Sheikhpour R.","year":"2014","journal-title":"Iranian Journal of Diabetes and Obesity"},{"issue":"4","key":"e_1_2_9_18_1","first-page":"182","article-title":"Evaluation of Immunoglobulin A in Diabetic Patients and Its Relation With Oral Complications","volume":"7","author":"Farahnak S.","year":"2015","journal-title":"Iranian Journal of Diabetes and Obesity"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.12.2135"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.04.06.dc05-0517"},{"issue":"8","key":"e_1_2_9_21_1","first-page":"S650","article-title":"Diabetic Neuropathy; Diagnostic Methods","volume":"4","author":"Cornbloth D. R.","year":"2004","journal-title":"Advanced Studies in Medicine"},{"issue":"4","key":"e_1_2_9_22_1","first-page":"593","article-title":"Comparison of Efficacy and Safety Profile of Empagliflozin Versus Dapagliflozin as Add on Therapy in Type 2 Diabetic Patients","volume":"33","author":"Hussain Mazaher M.","year":"2021","journal-title":"Journal of Ayub Medical College, Abbottabad"},{"issue":"6","key":"e_1_2_9_23_1","first-page":"11","article-title":"A Comparative Study of Efficacy and Safety of Different Sodium Glucose co\u2010Transporter 2 (SGLT\u20102) Inhibitors in the Management of Patients With Type II Diabetes Mellitus","volume":"70","author":"Bhosle D. S.","year":"2022","journal-title":"Journal of the Association of Physicians of India"},{"issue":"12","key":"e_1_2_9_24_1","first-page":"46","article-title":"Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians Not Controlled With at Least 4 Oral Antidiabetic Drugs","volume":"66","author":"Panikar V.","year":"2018","journal-title":"Journal of the Association of Physicians of India"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15183"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.5152\/AnatolJCardiol.2022.1934"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836365"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01103-9"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2024.01.027"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:13:53Z","timestamp":1767824033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/edm2.70128"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70128","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70128"}}